Tyrosine kinase inhibitors regulate serotonin uptake in platelets

Area of Science:

• Biochemistry
• Pharmacology
• Cell Biology

Background:

• Serotonin transporter (SERT) plays a crucial role in regulating serotonergic neurotransmission.
• Platelets are a valuable model for studying SERT due to their accessibility and high uptake capacity.
• Tyrosine kinase inhibitors (TKIs) are known to modulate various cellular processes.

Purpose of the Study:

• To investigate the effect of specific tyrosine kinase inhibitors, genistein and methyl 2,5-dihydroxycinnamate, on serotonin uptake in human platelets.
• To elucidate the mechanism underlying TKI-mediated inhibition of serotonin transporter activity.

Main Methods:

• Human platelet-rich plasma was used to measure the uptake of radiolabeled serotonin ([3H]serotonin).
• Binding studies were performed to assess the direct interaction of TKIs with the serotonin transporter.
• Intracellular calcium levels were manipulated using chelators to evaluate its role in TKI effects.

Main Results:

• Genistein and methyl 2,5-dihydroxycinnamate rapidly and potently inhibited [3H]serotonin uptake into human platelets.
• Inhibition of uptake did not correlate with direct binding of these TKIs to the serotonin transporter.
• Chelation of intracellular calcium did not prevent the inhibitory effects of genistein on serotonin uptake.

Conclusions:

• Tyrosine kinase inhibitors exert a direct inhibitory effect on serotonin uptake in human platelets.
• The mechanism of inhibition is independent of direct transporter binding and intracellular calcium signaling.
• These findings suggest novel regulatory pathways for serotonin transporter function involving tyrosine kinases.